Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meropenem and Pralurbactam in Complicated Intra-abdominal Infections
NCT06633718Phase 3Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Oct 2024
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pralubactam in Intra-abdominal infection (IAI), sponsored by Qilu Pharmaceutical. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
pralubactam
03
Conditions
Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on NCT06633718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06633718.